TGN 020

TGN 020 is an aquaporin-4 (AQP4) inhibitor (IC₅₀ = 3.1 μM in X. laevis oocytes transfected with AQP4).¹ It reduces brain edema and cortical infarction size in a mouse model of transient focal cerebral ischemia induced by middle cerebral artery occlusion (MCAO) when administered at a dose of 200 mg/kg.² TGN 020 (200 mg/kg every 6 hours) reduces bronchoalveolar lavage fluid (BALF) IL-1α, IL-1β, IL-6, TNF-α, IL-23, and IL-17A levels and neutrophil infiltration, as well as increases survival, in a mouse model of LPS-induced acute lung injury.³

WARNING This product is not for human or veterinary use.

1. Huber, V.J., Tsujita, M., and Nakada, T. Identification of aquaporin 4 inhibitors using in vitro and in silico methods. Bioorg. Med. Chem. 17(1), 411-417 (2009).

2. Igarashi, H., Huber, V.J., Tsujita, M., et al. Pretreatment with a novel aquaporin 4 inhibitor, TGN-020, significantly reduces ischemic cerebral edema. Neurol. Sci. 32(1), 113-116 (2011).

3. Guo, C., Wu, T., Zhu, H., et al. Aquaporin 4 blockade attenuates acute lung injury through inhibition of Th17 cell proliferation in mice. Inflammation 42(4), 1401-1412 (2019).